BIIB Q2 2024 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

Q2 2024 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$2.5B+0.4% YoY

Gross Profit

$1.5B61.2% margin

Operating Income

$367M14.9% margin

Net Income

$584M23.7% margin

EPS (Diluted)

$4.00

QoQ Revenue Growth

+7.6%

Cash Flow

Operating Cash Flow

$626M

Free Cash Flow

$583M

Stock-Based Comp.

$71M

Balance Sheet

Total Assets

$26.8B

Total Liabilities

$10.9B

Stockholders' Equity

$15.9B

Cash & Equivalents

$1.9B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.5B	$2.5B	+0.4%
Gross Profit	$1.5B	$1.9B	-19.0%
Operating Income	$367M	$690M	-46.9%
Net Income	$584M	$592M	-1.4%

Revenue Segments

MS Product Revenues

$1.1B42%

TYSABRI product

$462M17%

SPINRAZA

$429M16%

Fumarate

$418M15%

Interferon

$251M9%

Geographic Segments

Non-US

$1.1B55%

UNITED STATES

$847M45%